Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
 

 
 
 

Program Schedule 2014   >  Preliminary Program

Spacer
PRELIMINARY PROGRAM
Working titles/topics shown.  Final titles and speakers will follow.
Spacer

Tuesday, December 9, 2014

 
Spacer

EDUCATIONAL SESSIONS

Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

   
 

Breast Cancer is a Global Disease - Biology, Environment and Health Care Delivery

Moderator: Melissa Bondy, PhD

Baylor College of Medicine

Houston, TX

 

Global patterns of breast cancer

Benjamin O. Anderson, MD

University of Washington

Seattle, WA

 

Biology vs. Environment – Is biology driving health care disparities

Patricia Thompson, PhD

University of Arizona Cancer Center

Tucson, AZ

 

Breast cancer in developing countries - challenges and opportunities

Hamdy A. Azim, MSc, MD

Cairo University

Cairo, EGYPT

 

Breast Cancer Survivorship: One Size Does Not Fit All

Moderator: Polly Niravath, MD

Baylor College of Medicine

Houston, TX

 

Adherence and persistence with adjuvant aromatase inhibitor therapy

Norah Lynn Henry, MD, PhD

University of Michigan

Ann Arbor, MI

 

Second primary cancers among breast cancer survivors: Incidence and risk factors

Christopher I. Li, MD, PhD

Fred Hutchinson Cancer Research Center

Seattle, WA

 

Patient centered treatment summaries and survivorship care plans: enhancing clinical, cultural and linguistic responsiveness

Kimlin Tam Ashing, PhD

City of Hope Medical Center

Duarte, CA

 

HER2 Positive Breast Cancer: Insights from the Lab and Clinic

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

 

Mechanisms of HER2 signaling, targeting, and resistance

Mark M. Moasser, MD

University of California

San Francisco, CA

 

Neoadjuvant therapy in HER2 positive breast cancer, latest developments and biomarkers and how it serves as a discovery platform

Sibylle Loibl, MD, PhD

German Breast Group

Neu-Isenburg, GERMANY

 

Management of metastatic HER2 positive disease, how to use available agents and an overview of new products in development

Ian Krop, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

 

Introduction to Immunotherapy

Moderator: Douglas Yee, MD

University of Minnesota

Minneapolis, MN

 

Immunotherapeutic approaches to breast cancer

Mary L. (Nora) Disis, MD

University of Washington

Seattle, WA

 

Immune checkpoints and cancer therapy

Jeffrey S. Weber, MD, PhD

Moffitt Cancer Center

Tampa, FL

 

Tumor infiltrating lymphocytes in breast cancer

Sherene Loi, MBBS (Hons), FRACP, PhD

Peter MacCallum Cancer Centre

Melbourne, AUSTRALIA

 

Molecular Heterogeneity

Moderator: Andrea L. Richardson, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

 

Spatial and temporal evolution of breast cancer

Lucy Yates, MD

Cambridge Institute for Medical Research

Cambridge, UNITED KINGDOM

 

Circulating plasma tumor DNA as biomarkers for breast cancer therapy

Ben Ho Park, MD, PhD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, MD

 

Epigenetic heterogeneity in cancer

Kornelia Polyak, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

 

Neoadjuvant Treatment of ER+ Breast Cancer

Moderator: Professor Mitchell Dowsett

Royal Marsden Hospital

London, UNITED KINGDOM

 

Clinical insights on the neoadjuvant therapy of ER+ breast cancer

David Cameron, MD

Edinburgh Cancer Research Centre

Edinburgh, UNITED KINGDOM

 

Biomarkers for clinical management and research

Professor Mitchell Dowsett

Royal Marsden Hospital

London, UNITED KINGDOM

 

Integration of novel targeted agents with endocrine therapy

Ingrid A. Mayer, MD, MSCI

Vanderbilt University School of Medicine

Nashville, TN

 

New Insights in Breast Radiation

Moderator: Richard L. Crownover, MD, PhD

UT Health Science Center

San Antonio, TX

 

Which patients can safely avoid radiation after breast conserving surgery?

Professor Ian Kunkler

University of Edinburgh

Edinburgh, UNITED KINGDOM

 

What have we learned from the randomized trials of partial breast RT?

Professor Ivo Olivotto

University of Calgary and Tom Baker Cancer Centre

Calgary, CANADA

 

What is the value of internal mammary chain RT and how can we deliver it safely?

Professor John R. Yarnold

Royal Marsden and Institute of Cancer Research

London, UNITED KINGDOM

 

Optimizing Clinical Outcomes and Quality of Life in Breast Reconstruction

Moderator: John Benson, MD

Cambridge University Hospitals NHS Foundation Trust

Cambridge, UNITED KINGDOM

 

The impact of patient perspective on outcomes in breast reconstruction

Andrea L. Pusic, MD, MHS

Memorial Sloan-Kettering Cancer Center

New York, NY

 

Reconstruction for the high risk patient: challenges of chemotherapy, radiation therapy and patient selection

Mehra Golshan, MD

Brigham and Women's Hospital

Boston, MA

 

Delayed and immediate partial breast reconstruction after breast conserving surgery

Krishna B. Clough, MD

L 'Institut du Sein-Paris Breast Centre

Paris, FRANCE

 

Triple Negative Breast Cancer

Moderator: Nicholas Turner, PhD, FRCP

Royal Marsden and Institute of Cancer Research

London, UNITED KINGDOM

 

The clinical significance of heterogeneity in triple negative breast cancer

Nicholas Turner, PhD, FRCP

Royal Marsden and Institute of Cancer Research

London, UNITED KINGDOM

 

Targeting the positives in TNBC – platinums, PARPS and novel approaches to high risk disease

Andrew Tutt, Dr Med

Institute of Cancer Research and King's College London

London, UNITED KINGDOM

 

Adjuvant and neoadjuvant therapy: Current practice and future approaches

Eric P. Winer, MD

Dana-Farber Cancer Institute

Boston, MA

 
Top
Spacer
AWARD LECTURES
Spacer
Exhibit Hall D  
 

William L. McGuire Memorial Lecture

Pharmacogenomics in the Quest for Precision Endocrine Therapy of Breast Cancer

James N. Ingle, MD

Mayo Clinic

Rochester, MN

   
 

AACR Distinguished Lectureship in Breast Cancer Research

TBA

Mary-Claire King, PhD

University of Washington

Seattle, WA

   
 

AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen®

   
 

Susan G. Komen® Brinker Awards for Scientific Distinction Lectures

 
Top
Spacer
PLENARY LECTURES

 

Spacer
Exhibit Hall D  
 

Adjuvant Endocrine Therapy in 2015

Nancy E. Davidson, MD

University of Pittsburgh

Pittsburgh, PA

Genome-Directed Therapeutics for Endocrine Therapy Resistant ER+ Breast Cancer

Matthew J. Ellis, MD, PhD

Washington University School of Medicine

St. Louis, MO

Patient Derived Xenografts - Pre-Clinical Models for Prevention and Treatment of Metastasis

Alana L. Welm, PhD

Oklahoma Medical Research Foundation

Oklahoma City, OK

 

 
Top
Spacer
MINI-SYMPOSIA  
Spacer
Exhibit Hall D  
 

Targeting Epigenetics in Breast Cancer

Moderator: Vered Stearns, MD

John Hopkins University School of Medicine

Baltimore, MD

 

TBA

Peter W. Laird, PhD

University of Southern California

Los Angeles, CA

 

TBA

Vered Stearns, MD

The Sidney Kimmel Comprehensive Cancer Center

at Johns Hopkins

Baltimore, MD

 

Breast Cancer Predisposition: Germline and Risk

Moderator: Laura J. van 't Veer, PhD

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, CA

 

Characterising cancer risks for carriers of mutations in BRCA1, BRCA2, PALB2 and RAD51C genes

Antonis Antoniou

University of Cambridge

Cambridge, UNITED KINGDOM

 

TBA

Banu Arun, MD

UT MD Anderson Cancer Center

Houston, TX

 
Top
Spacer

THE YEAR IN REVIEW

Saturday, December 13, 2014

 
Spacer
Exhibit Hall D  
 

Moderator: C. Kent Osborne, MD

Baylor College of Medicine

Houston, TX

Basic

Charlotte Kuperwasser, PhD

Tufts University School of Medicine

Boston, MA

Translational

Jorge S. Reis-Filho, MD, PHD, FRCPath

Memorial Sloan-Kettering Cancer Center

New York, NY

Adjuvant

Harold J. Burstein, MD, PhD

Dana-Farber Cancer Institute

Boston, MA

Metastatic

William J. Gradishar, MD

Northwestern University Feinberg School of Medicine

Chicago, IL

 
Top
Spacer
BASIC SCIENCE FORUMS

 

Spacer
Ballroom B  
 

Discovering Rational Combination Therapies

Moderator: Carlos Arteaga, MD

Vanderbilt-Ingram Cancer Center

Vanderbilt University

Nashville, TN

 

Targeting DNA repair in triple negative breast cancer therapy

Alan D'Andrea, MD

Dana-Farber Cancer Institute

Boston, MA

 

Finding effective combination therapies through functional genetics

René Bernards, PhD

Netherlands Cancer Institute

Amsterdam, NETHERLANDS

 

How Do Mutations Occur in Breast Cancer?

Moderator: Douglas Yee, MD

University of Minnesota

Minneapolis, MN

 

APOBEC3B-catalyzed mutagenesis in breast cancer

Reuben Harris, PhD

University of Minnesota

Minneapolis, MN

 

RNA editing and cancer stem cell generation

Catriona Jamieson, MD, PhD

UCSD Moore Cancer Center

La Jolla, CA

 

New Insights into Metastatic Progression

Moderator: Xiang Zhang, PhD

Baylor College of Medicine

Houston, TX

 

Collective invasion in breast cancer is led by specialized cancer cells with basal gene expression

Andrew Ewald, PhD

Johns Hopkins University School of Medicine

Baltimore, MD

 

Targeting the LIFR-Hippo-YAP pathway as an anti-metastatic strategy

Li Ma, PhD

UT MD Anderson Cancer Center

Houston, TX

 

 
Top
Spacer
CLINICAL SCIENCE FORUM  
Spacer
Ballroom A  
 

Contralateral Prophylactic Mastectomy: Controversies and Trends

Moderator: Ismail Jatoi, MD, PhD, FACS

UT Health Science Center at San Antonio

San Antonio, TX

 

Clinical implications of contralateral prophylactic mastectomy

Ismail Jatoi, MD, PhD, FACS

UT Health Science Center at San Antonio

San Antonio, TX

 

Contralateral prophylactic mastectomy: Patient preferences and risk perceptions

Ann Partridge, MD, MPH

Dana-Farber Cancer Institute

Boston, MA

 

What are the implications for reconstruction following contralateral prophylactic mastectomy?

Andrea L. Pusic, MD, MHS

Memorial Sloan-Kettering Cancer Center

New York, NY

 

 
Top
SPECIAL FORUM  
   
 

Role of Advocates in Legislation, Research and Community Support

Moderator: Susan W. Rafte

Pink Ribbons Project

Houston, TX

 

Jane Perlmutter, PhD, MBA

Gemini Group

Ann Arbor, MI

 

Elizabeth Frank

Dana-Farber Cancer Institute

Boston, MA

 

Valarie Worthy

Duke Cancer Institute

Durham, NC

 

Accelerating International Drug Development, Companion Diagnostics, and Their Approval

Moderator: Laura J. van 't Veer, PhD

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, CA

 

Government Perspective

Speaker to be determined

 

Collaborative Group Perspective

Jan H. M. Schellens, MD, PhD

The Netherlands Cancer Institute

Amsterdam, NETHERLANDS

SPECIAL SATELLITE SYMPOSIUM

 

   

Henry B. Gonzalez Convention Center
Friday, December 12, 2014

7:30 PM

Minimal requirements and radiation therapy standards for breast cancer in countries with limited resources

Presented by Association of Radiotherapy and Oncology of the Mediterranean Area (AROME)

http://www.aromecancer.org

 

This workshop presentation will help to achieve the goal of overcoming the inequalities in radiation oncology clinical practices that are the result of not being able to follow existing guidelines that were developed primarily for countries with unlimited resources.

 

A panel of internationally recognized experts will present potential solutions on bridging the gap between countries in terms of decision making, multidisciplinary teamwork and ownership of adopted guidelines. Not only will this symposium be a significant resource for SABCS attendees in general but also will be a particularly important educational opportunity for international attendees who come from places where limited resources are a reality.

   
Spacer
CASE DISCUSSIONS  
Spacer
Ballroom A

 

 

Moderator: Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

 
Top
Spacer
CAREER DEVELOPMENT FORUM: A NETWORKING SESSION FOR YOUNG INVESTIGATORS  
Spacer
Tuesday, December 9, 2014

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2014 SABCS. Space in the workshop is limited to 220 participants; registrations will be accepted on a first-come, first-served basis and is free of charge.  You can register for this session when you register for the Symposium.

 
Top
Spacer
PRELIMINARY SCHEDULE
Hours subject to change.
Spacer

Tuesday, December 9

Registration

Program (Educational Sessions)

 

8:00 AM-7:00 PM

12:00 PM-7:00 PM

Wednesday, December 10

Registration

Program (Main Program begins)

Exhibits

 

7:00 AM-5:15 PM

8:00 AM-7:00 PM

11:00 AM-5:00 PM

Thursday, December 11

Registration

Program

Exhibits

 

7:00 AM-5:15 PM

7:30 AM-7:00 PM

11:00 AM-5:00 PM

Friday, December 12

Registration

Program

Exhibits

 

7:00 AM-5:15 PM

7:30 AM-7:00 PM

11:00 AM-5:00 PM

Saturday, December 13

Registration

Program

 

7:00 AM-9:00 AM

7:30 AM-11:00 AM

 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright 2014 SABCS. All rights reserved. - Privacy Policy